| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy | 55 | 2025 | 1529 | 4.460 |
Why?
|
| Cannabis | 11 | 2025 | 82 | 4.320 |
Why?
|
| Prenatal Exposure Delayed Effects | 8 | 2025 | 167 | 3.830 |
Why?
|
| Depression, Postpartum | 5 | 2025 | 19 | 3.780 |
Why?
|
| Depression | 10 | 2024 | 506 | 3.590 |
Why?
|
| Female | 73 | 2025 | 12780 | 2.690 |
Why?
|
| Alcohol Drinking | 10 | 2025 | 373 | 2.510 |
Why?
|
| Adult | 54 | 2025 | 7708 | 2.350 |
Why?
|
| Humans | 74 | 2025 | 17822 | 2.280 |
Why?
|
| Anxiety | 6 | 2024 | 151 | 2.180 |
Why?
|
| Premature Birth | 8 | 2023 | 137 | 2.110 |
Why?
|
| California | 24 | 2025 | 2328 | 2.070 |
Why?
|
| Pregnancy Complications | 7 | 2024 | 201 | 2.060 |
Why?
|
| Pregnant Women | 3 | 2023 | 45 | 1.670 |
Why?
|
| Exercise | 4 | 2025 | 495 | 1.630 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2022 | 146 | 1.550 |
Why?
|
| Hallucinogens | 2 | 2022 | 23 | 1.520 |
Why?
|
| Telemedicine | 2 | 2025 | 187 | 1.500 |
Why?
|
| Autism Spectrum Disorder | 2 | 2024 | 164 | 1.470 |
Why?
|
| Intimate Partner Violence | 2 | 2023 | 11 | 1.400 |
Why?
|
| Postpartum Period | 3 | 2025 | 97 | 1.300 |
Why?
|
| Pandemics | 8 | 2023 | 287 | 1.260 |
Why?
|
| Marijuana Use | 4 | 2024 | 37 | 1.200 |
Why?
|
| Prenatal Care | 5 | 2024 | 130 | 1.170 |
Why?
|
| Abortion, Spontaneous | 3 | 2014 | 47 | 1.150 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 1335 | 1.090 |
Why?
|
| Substance-Related Disorders | 6 | 2022 | 434 | 1.060 |
Why?
|
| Perinatal Care | 2 | 2016 | 12 | 1.050 |
Why?
|
| Nicotine | 2 | 2025 | 50 | 0.990 |
Why?
|
| Cohort Studies | 15 | 2024 | 2590 | 0.970 |
Why?
|
| Pregnancy Outcome | 5 | 2023 | 158 | 0.960 |
Why?
|
| Legislation, Drug | 2 | 2024 | 10 | 0.960 |
Why?
|
| Infant, Newborn | 14 | 2025 | 858 | 0.950 |
Why?
|
| Hearing Loss | 1 | 2025 | 19 | 0.950 |
Why?
|
| Anxiety Disorders | 4 | 2023 | 91 | 0.930 |
Why?
|
| Young Adult | 16 | 2024 | 2464 | 0.930 |
Why?
|
| Developmental Disabilities | 1 | 2024 | 52 | 0.900 |
Why?
|
| Child Development | 2 | 2024 | 54 | 0.880 |
Why?
|
| Overweight | 2 | 2022 | 270 | 0.870 |
Why?
|
| Influenza, Human | 4 | 2020 | 265 | 0.820 |
Why?
|
| Adolescent | 17 | 2023 | 3690 | 0.810 |
Why?
|
| Vitamins | 4 | 2022 | 64 | 0.810 |
Why?
|
| Stress, Psychological | 4 | 2022 | 141 | 0.800 |
Why?
|
| Pre-Eclampsia | 3 | 2023 | 44 | 0.790 |
Why?
|
| Autistic Disorder | 1 | 2023 | 100 | 0.790 |
Why?
|
| Male | 22 | 2025 | 10145 | 0.760 |
Why?
|
| Influenza Vaccines | 4 | 2020 | 273 | 0.750 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 40 | 0.740 |
Why?
|
| Dietary Supplements | 3 | 2014 | 87 | 0.720 |
Why?
|
| Alcoholism | 7 | 2009 | 348 | 0.710 |
Why?
|
| Temperature | 2 | 2017 | 19 | 0.690 |
Why?
|
| Retrospective Studies | 10 | 2025 | 2467 | 0.670 |
Why?
|
| Infant | 8 | 2025 | 1198 | 0.670 |
Why?
|
| Marijuana Smoking | 1 | 2020 | 52 | 0.650 |
Why?
|
| Health Plan Implementation | 2 | 2016 | 36 | 0.640 |
Why?
|
| Diet | 2 | 2024 | 366 | 0.620 |
Why?
|
| Child | 10 | 2024 | 2497 | 0.590 |
Why?
|
| Depressive Disorder | 1 | 2020 | 222 | 0.580 |
Why?
|
| Spouse Abuse | 1 | 2017 | 8 | 0.580 |
Why?
|
| Alcoholics Anonymous | 4 | 2011 | 14 | 0.560 |
Why?
|
| Risk-Taking | 2 | 2009 | 109 | 0.530 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2016 | 228 | 0.530 |
Why?
|
| Risk Factors | 8 | 2025 | 3362 | 0.510 |
Why?
|
| Child, Preschool | 7 | 2024 | 1424 | 0.500 |
Why?
|
| Temperance | 3 | 2012 | 24 | 0.490 |
Why?
|
| Health | 2 | 2015 | 33 | 0.490 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2015 | 9 | 0.480 |
Why?
|
| Computers | 1 | 2014 | 6 | 0.480 |
Why?
|
| Dietary Carbohydrates | 1 | 2014 | 27 | 0.480 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2015 | 28 | 0.480 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 14 | 0.470 |
Why?
|
| Beer | 1 | 2014 | 9 | 0.460 |
Why?
|
| Wine | 1 | 2014 | 18 | 0.460 |
Why?
|
| Antiviral Agents | 2 | 2014 | 95 | 0.450 |
Why?
|
| Pregnancy Trimester, First | 1 | 2014 | 40 | 0.450 |
Why?
|
| Aging | 2 | 2015 | 163 | 0.450 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 22 | 0.440 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2024 | 57 | 0.430 |
Why?
|
| United States | 13 | 2023 | 4007 | 0.430 |
Why?
|
| Counseling | 1 | 2014 | 189 | 0.420 |
Why?
|
| Life Tables | 1 | 2012 | 9 | 0.400 |
Why?
|
| Delivery of Health Care | 4 | 2023 | 417 | 0.390 |
Why?
|
| Mental Health | 2 | 2024 | 166 | 0.390 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2011 | 6 | 0.390 |
Why?
|
| Pediatric Obesity | 2 | 2024 | 85 | 0.370 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2011 | 75 | 0.360 |
Why?
|
| Surveys and Questionnaires | 8 | 2017 | 1323 | 0.360 |
Why?
|
| African Continental Ancestry Group | 1 | 2011 | 162 | 0.360 |
Why?
|
| Social Support | 3 | 2011 | 207 | 0.360 |
Why?
|
| Maternal Exposure | 2 | 2024 | 62 | 0.360 |
Why?
|
| Community Mental Health Services | 2 | 2008 | 33 | 0.350 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2022 | 46 | 0.350 |
Why?
|
| Social Environment | 2 | 2008 | 88 | 0.350 |
Why?
|
| Patient Compliance | 2 | 2009 | 301 | 0.330 |
Why?
|
| European Continental Ancestry Group | 1 | 2011 | 529 | 0.320 |
Why?
|
| Mass Screening | 1 | 2014 | 678 | 0.320 |
Why?
|
| Middle Aged | 12 | 2021 | 8020 | 0.310 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 69 | 0.310 |
Why?
|
| Psychometrics | 3 | 2023 | 121 | 0.300 |
Why?
|
| Interpersonal Relations | 2 | 2008 | 42 | 0.300 |
Why?
|
| Body Mass Index | 3 | 2022 | 967 | 0.300 |
Why?
|
| Sexual Behavior | 1 | 2009 | 124 | 0.290 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 720 | 0.290 |
Why?
|
| Seasons | 2 | 2017 | 105 | 0.270 |
Why?
|
| Maternal Health Services | 2 | 2016 | 13 | 0.260 |
Why?
|
| Hispanic Americans | 2 | 2020 | 404 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2020 | 1103 | 0.260 |
Why?
|
| Prevalence | 6 | 2014 | 888 | 0.260 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.250 |
Why?
|
| Computational Biology | 1 | 2015 | 27 | 0.250 |
Why?
|
| Maternal Age | 2 | 2017 | 77 | 0.250 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 77 | 0.240 |
Why?
|
| Genomics | 1 | 2015 | 55 | 0.240 |
Why?
|
| Organophosphates | 1 | 2024 | 9 | 0.240 |
Why?
|
| Flame Retardants | 1 | 2024 | 11 | 0.240 |
Why?
|
| Self-Help Groups | 1 | 2004 | 30 | 0.230 |
Why?
|
| Marital Status | 1 | 2004 | 21 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 321 | 0.220 |
Why?
|
| Social Segregation | 1 | 2023 | 2 | 0.220 |
Why?
|
| Smoking | 3 | 2017 | 484 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2020 | 1286 | 0.220 |
Why?
|
| Eclampsia | 1 | 2023 | 12 | 0.220 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2023 | 5 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2015 | 391 | 0.210 |
Why?
|
| Continental Population Groups | 1 | 2015 | 302 | 0.210 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 8 | 0.210 |
Why?
|
| Primary Health Care | 1 | 2009 | 770 | 0.210 |
Why?
|
| Folic Acid | 1 | 2022 | 32 | 0.210 |
Why?
|
| Analgesics | 1 | 2022 | 27 | 0.200 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 27 | 0.200 |
Why?
|
| Drug Utilization | 2 | 2013 | 128 | 0.200 |
Why?
|
| Labetalol | 1 | 2022 | 9 | 0.200 |
Why?
|
| Socioeconomic Factors | 5 | 2017 | 630 | 0.200 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 35 | 0.190 |
Why?
|
| Cannabinoids | 1 | 2021 | 6 | 0.190 |
Why?
|
| Ethnic Groups | 1 | 2015 | 485 | 0.190 |
Why?
|
| Calcineurin Inhibitors | 1 | 2020 | 2 | 0.180 |
Why?
|
| Cholesterol, HDL | 1 | 2021 | 81 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2020 | 23 | 0.180 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 13 | 0.180 |
Why?
|
| Triglycerides | 1 | 2021 | 89 | 0.180 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2020 | 24 | 0.170 |
Why?
|
| Gestational Age | 3 | 2023 | 112 | 0.170 |
Why?
|
| Self Medication | 1 | 2020 | 5 | 0.170 |
Why?
|
| Psychological Trauma | 1 | 2020 | 6 | 0.170 |
Why?
|
| Ideal Body Weight | 1 | 2020 | 10 | 0.170 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2020 | 11 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 55 | 0.170 |
Why?
|
| Fruit | 1 | 2020 | 79 | 0.170 |
Why?
|
| Vegetables | 1 | 2020 | 87 | 0.170 |
Why?
|
| Vaccines, Inactivated | 1 | 2020 | 67 | 0.170 |
Why?
|
| Time Factors | 2 | 2014 | 1097 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 57 | 0.170 |
Why?
|
| Ethanol | 2 | 2023 | 22 | 0.170 |
Why?
|
| Energy Intake | 1 | 2020 | 101 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2020 | 27 | 0.170 |
Why?
|
| Obesity | 2 | 2022 | 842 | 0.160 |
Why?
|
| HIV Infections | 1 | 2005 | 707 | 0.150 |
Why?
|
| Women's Health | 2 | 2021 | 202 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 1219 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2013 | 1265 | 0.140 |
Why?
|
| Weather | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 47 | 0.140 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 30 | 0.140 |
Why?
|
| Drug Prescriptions | 2 | 2020 | 151 | 0.130 |
Why?
|
| Risk | 2 | 2014 | 518 | 0.130 |
Why?
|
| Medicaid | 1 | 2017 | 190 | 0.120 |
Why?
|
| Molecular Epidemiology | 2 | 2015 | 44 | 0.120 |
Why?
|
| Data Collection | 2 | 2007 | 257 | 0.120 |
Why?
|
| Breast Feeding | 1 | 2017 | 137 | 0.120 |
Why?
|
| Hypertension | 1 | 2020 | 505 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2014 | 264 | 0.120 |
Why?
|
| Herpes Genitalis | 1 | 2014 | 3 | 0.120 |
Why?
|
| Labor, Induced | 1 | 2014 | 6 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 315 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2020 | 698 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2014 | 114 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2014 | 69 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 100 | 0.110 |
Why?
|
| Health Behavior | 2 | 2014 | 360 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2014 | 219 | 0.110 |
Why?
|
| African Americans | 1 | 2017 | 472 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2014 | 106 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 86 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2014 | 160 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 2012 | 9 | 0.100 |
Why?
|
| Prescriptions | 1 | 2013 | 27 | 0.100 |
Why?
|
| Epilepsy | 1 | 2012 | 13 | 0.100 |
Why?
|
| Educational Status | 3 | 2023 | 200 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2013 | 77 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2013 | 49 | 0.100 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 6 | 0.100 |
Why?
|
| Abortion, Induced | 1 | 2012 | 18 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2013 | 137 | 0.100 |
Why?
|
| Mothers | 2 | 2022 | 106 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 272 | 0.090 |
Why?
|
| Vaccination | 1 | 2015 | 655 | 0.090 |
Why?
|
| Antihypertensive Agents | 2 | 2022 | 161 | 0.080 |
Why?
|
| South Africa | 1 | 2009 | 17 | 0.080 |
Why?
|
| Tobacco | 2 | 2023 | 14 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 346 | 0.080 |
Why?
|
| Helping Behavior | 1 | 2007 | 2 | 0.070 |
Why?
|
| Logistic Models | 3 | 2017 | 928 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 455 | 0.060 |
Why?
|
| Day Care, Medical | 1 | 2005 | 2 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 644 | 0.060 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 23 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 23 | 0.060 |
Why?
|
| Quality Control | 1 | 2015 | 45 | 0.060 |
Why?
|
| Pedigree | 1 | 2015 | 61 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 101 | 0.060 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2005 | 102 | 0.060 |
Why?
|
| Esters | 1 | 2024 | 5 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 569 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 79 | 0.060 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 48 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 329 | 0.060 |
Why?
|
| Aged | 3 | 2020 | 6173 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 379 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 31 | 0.050 |
Why?
|
| Motivation | 1 | 2004 | 131 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 29 | 0.050 |
Why?
|
| Self Report | 1 | 2024 | 253 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 11 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 381 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2005 | 172 | 0.050 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 537 | 0.050 |
Why?
|
| Methyldopa | 1 | 2022 | 6 | 0.050 |
Why?
|
| Accelerometry | 1 | 2022 | 39 | 0.050 |
Why?
|
| Nifedipine | 1 | 2022 | 7 | 0.050 |
Why?
|
| Sleep | 1 | 2022 | 58 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2020 | 4 | 0.040 |
Why?
|
| Menopause | 1 | 2021 | 69 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 119 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 246 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 95 | 0.040 |
Why?
|
| Weight Gain | 1 | 2020 | 173 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2012 | 223 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 810 | 0.040 |
Why?
|
| Environment | 1 | 2016 | 52 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1269 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 2014 | 13 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2016 | 325 | 0.030 |
Why?
|
| Preconception Care | 1 | 2014 | 44 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 376 | 0.030 |
Why?
|
| Oregon | 1 | 2013 | 181 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2013 | 17 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2013 | 12 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2013 | 25 | 0.030 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2013 | 19 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2014 | 194 | 0.030 |
Why?
|
| Binge Drinking | 1 | 2012 | 8 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 85 | 0.030 |
Why?
|
| Metformin | 1 | 2013 | 58 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 382 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 230 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1120 | 0.020 |
Why?
|
| Antisocial Personality Disorder | 1 | 2006 | 3 | 0.020 |
Why?
|
| Marriage | 1 | 2006 | 5 | 0.020 |
Why?
|
| Military Personnel | 1 | 2006 | 12 | 0.020 |
Why?
|
| Behavior | 1 | 2006 | 18 | 0.020 |
Why?
|
| Aggression | 1 | 2006 | 19 | 0.020 |
Why?
|
| Episode of Care | 1 | 2005 | 14 | 0.020 |
Why?
|
| Aftercare | 1 | 2005 | 49 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2006 | 64 | 0.020 |
Why?
|
| Family | 1 | 2006 | 112 | 0.020 |
Why?
|
| Recurrence | 1 | 2005 | 189 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2005 | 114 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 250 | 0.010 |
Why?
|
| Parents | 1 | 2006 | 297 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 292 | 0.010 |
Why?
|